News & Media

20232022202120202019201820172016201520142013
Press release 2023/09/14
Medivir to present at the Pareto Securities Healthcare Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/09/11
Medivir´s Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/09/07
Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancers with high unmet medical...

Read more
Press release 2023/09/04 Regulatory
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima

Central review of the 6 patients in phase 1b dose escalation part was performed In these 6 patients, complete response was...

Read more
Press release 2023/09/01
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/08/23
Medivir to present at the Erik Penser Bank Company Event

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/08/18 Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2023

Continued strong momentum and promising signs of patient benefit in the combination study with fostrox and Lenvima® April – June Financial...

Read more
Press release 2023/08/14
Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

Continued tumor control in the liver in 7 of the first 10 patients after three months of treatment The patient who...

Read more
Press release 2023/08/07
Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/06/19
Medivir's patent application for fostrox approved in China

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/06/02
Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/06/01
Medivir to present at the Redeye Growth Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more